Location: Solmed Polyclinic (Zagreb)
Study Drug: Experimental biological therapy that blocks the effect of the pro-inflammatory molecule TL1A.
Main Inclusion Criteria: Patients aged 18 and older with an official diagnosis of ulcerative colitis who, with at least one previous line of treatment (either conventional or biological therapy), have symptoms of active disease.
Status: Enrolling new patients soon
Start of patient enrollment: July 2024.
Planned completion of patient enrollment: May 2026.